by Vora Corporate Finance | Jun 14, 2021 | Articles, Capital Market Updates, Merger & Acquisitions, Private Equity & IPO
The new year 2021 has begun on a strong positive note with vaccination drives ikn major economies as well as in India. The COVID-19 incidence is seen receding and economic recovery was seen. The economic survey and union budget were presented in February and their...
by Vora Corporate Finance | Jun 10, 2021 | Financial Advisory, Insights
BSE Sensex went up by 6.47% to close at 51,937 in May 2021. Nifty 50 closed at 15,583 higher by 6.50% from 14,631 in April closing. On 24 May 2021, the combined market value of companies listed on the Bombay Stock Exchange (BSE) crossed the US $3 trillion mark for the...
by Vora Corporate Finance | May 28, 2021 | Financial Advisory, Insights, Merger & Acquisitions, Private Equity & IPO
Indian Economy’s recovery pace moderated in April on account of 2nd Covid-19 wave with record infections. Markets remained stable in this month but two IPOs were listed at discount. Key Deals include BYJU’S to acquire Aakash, Piramal to Acquire Hemmo Pharmaceuticals...
by Vora Corporate Finance | May 21, 2021 | Financial Advisory, Insights, Merger & Acquisitions
Transaction: Piramal Pharma Limited to acquire a 100% stake in Hemmo Pharmaceuticals Pvt. Ltd. for an upfront consideration of Rs.775 crores and earn-outs linked to achievement of milestones. Consequent to this acquisition, Hemmo will become a wholly owned subsidiary...
by Vora Corporate Finance | May 20, 2021 | Financial Advisory, Insights, Private Equity & IPO
Transaction: Creador sold its stake in Ahmedabad based Corona Remedies to PE fund ChrysCapital. ChrysCapital paid Rs.6.7 billion ($90 million) for a 30% stake, of which 20% came from Creador and 10% from the promoter group. The deal values Corona Remedies at around...
